Xinda Biotech (01801) has completed a global strategic cooperation with Takeda Pharmaceuticals and has issued 691.38 million shares under general authorization.

Wisdom Finance APP news, Xinda Bio (01801) announced that Xinda Bio has reached a global strategic cooperation agreement with Takeda Pharmaceutical (through Takeda Pharmaceutical's wholly-owned subsidiary Takeda Pharmaceuticals International AG), and all the preconditions of the license, option and cooperation agreement and the share issuance agreement have been met or waived (as applicable). Therefore, the license, option and cooperation agreements have been completed and the share issuance agreement will be completed on December 4, 2025.